Confusable diagnoses · PANCE / PANRE

Acute Myeloid Leukemia vs Chronic Myeloid Leukemia

Written & clinically reviewed by Ryan Busch, PA-C · Updated August 2026 · Report an error

Acute Myeloid Leukemia and Chronic Myeloid Leukemia are easy to mix up on the boards. Here's a side-by-side comparison — presentation, workup, imaging, and first-line treatment — drawn from our full outlines.

Acute Myeloid Leukemia vs Chronic Myeloid Leukemia at a glance

  • Acute Myeloid Leukemia: Clonal expansion of myeloid blasts in marrow and blood — pancytopenia plus circulating blasts; APL subtype is a hemorrhagic emergency.
  • Chronic Myeloid Leukemia: Myeloproliferative neoplasm defined by the Philadelphia chromosome (BCR-ABL1) — transformed by targeted TKI therapy into a chronic, manageable disease.

Try two board-style questions on Acute Myeloid Leukemia vs Chronic Myeloid Leukemia

Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.

Question 1HematologyMedium
A 67-year-old man is admitted with 3 weeks of progressive fatigue, dyspnea on exertion, gum bleeding, and several scattered bruises. Examination shows conjunctival pallor and petechiae over both shins. Laboratory studies show hemoglobin 7.6 g/dL, platelet count 18,000/µL, and an absolute neutrophil count of 400/µL. The peripheral smear shows numerous large myeloblasts, some containing eosinophilic needle-like cytoplasmic inclusions. Bone marrow biopsy reveals 65% myeloblasts. Which of the following best explains his anemia, thrombocytopenia, and neutropenia?
  • AIneffective hematopoiesis with intramedullary apoptosis of mature precursors
  • BMarrow crowding by proliferating myeloblasts suppressing normal hematopoiesis
  • CAutoantibody-mediated peripheral destruction of mature circulating blood cells
  • DSplenic sequestration of circulating mature erythrocytes and platelets
Reveal answer & full explanation
Correct answer: B — Marrow crowding by proliferating myeloblasts suppressing normal hematopoiesis
  • AIneffective hematopoiesis with intramedullary apoptosis of mature precursors
  • BMarrow crowding by proliferating myeloblasts suppressing normal hematopoiesis✓
  • CAutoantibody-mediated peripheral destruction of mature circulating blood cells
  • DSplenic sequestration of circulating mature erythrocytes and platelets

Why Marrow crowding by proliferating myeloblasts suppressing normal hematopoiesis is correct

  • In AML, acquired genetic/epigenetic lesions (e.g., FLT3, NPM1, CEBPA, IDH1/2) block myeloid differentiation while driving blast proliferation.
  • The expanding clone of myeloblasts fills the marrow space (here 65% blasts) and suppresses normal erythroid, megakaryocytic, and granulocytic production, producing the triad of anemia, thrombocytopenia, and neutropenia.
  • The needle-like inclusions are Auer rods, pathognomonic for AML and confirming a myeloid blast process.

Why the others are wrong

  • Autoantibody-mediated peripheral destruction of mature circulating blood cells is the mechanism of autoimmune cytopenias (immune thrombocytopenia, autoimmune hemolytic anemia); it does not produce a marrow packed with 65% myeloblasts.
  • Splenic sequestration of circulating mature erythrocytes and platelets occurs in hypersplenism, where peripheral pooling drives cytopenias but the marrow stays cellular with normal maturing lineages rather than blast-filled.
  • Ineffective hematopoiesis with intramedullary apoptosis of mature precursors describes myelodysplastic syndrome or megaloblastic anemia, where a hypercellular marrow shows dysplastic but maturing precursors and fewer than 20% blasts, not 65% blasts with Auer rods.
Question 2HematologyMedium
A 52-year-old man has fatigue and splenomegaly. WBC is 78,000 with left-shifted myeloid cells at all stages of maturation. Cytogenetics shows t(9;22)(q34;q11). Which molecular abnormality results from this translocation?
  • APML-RARA fusion
  • BBCR-ABL fusion
  • CJAK2 V617F mutation
  • DFLT3-ITD mutation
Reveal answer & full explanation
Correct answer: B — BCR-ABL fusion
  • APML-RARA fusion
  • BBCR-ABL fusion✓
  • CJAK2 V617F mutation
  • DFLT3-ITD mutation

Why BCR-ABL fusion is correct

  • Chronic myeloid leukemia (CML): t(9;22) creates the Philadelphia chromosome, fusing BCR (chr 22) with ABL1 (chr 9)
  • The resulting BCR-ABL fusion protein is a constitutively active tyrosine kinase that drives myeloid proliferation
  • Imatinib (Gleevec) and other tyrosine kinase inhibitors (dasatinib, nilotinib) bind the ATP-binding pocket of BCR-ABL, dramatically improving prognosis
  • CML has three phases: chronic, accelerated, and blast crisis

Why the others are wrong

  • A) PML-RARA fusion — PML-RARA results from t(15;17) and causes acute promyelocytic leukemia (APL) (AML M3); treated with all-trans retinoic acid (ATRA) + arsenic; carries risk of disseminated intravascular coagulation (DIC)
  • C) JAK2 V617F mutation — JAK2 V617F is associated with myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis; treated with ruxolitinib
  • D) FLT3-ITD mutation — FLT3-ITD occurs in acute myeloid leukemia (AML) and confers poor prognosis; treated with midostaurin
🔒 Free preview limit reached

Keep comparing — start your free trial

You've used your 2 free previews. Create your free account to see the full Acute Myeloid Leukemia vs Chronic Myeloid Leukemia comparison — plus all 514 diagnosis outlines, 7,200+ board-style questions, and an AI tutor. Your 7-day free trial includes everything, no credit card required.

Start your 7-day free trial → Sign in
Free to start · No credit card · Cancel anytime

Side-by-side comparison

FeatureAcute Myeloid LeukemiaChronic Myeloid Leukemia
At a glanceClonal expansion of myeloid blasts in marrow and blood — pancytopenia plus circulating blasts; APL subtype is a hemorrhagic emergency.Myeloproliferative neoplasm defined by the Philadelphia chromosome (BCR-ABL1) — transformed by targeted TKI therapy into a chronic, manageable disease.
Classic presentationOlder adult with pancytopenia, fatigue, petechiae, and Auer rods on blast smear. APL: severe DIC with intracranial or pulmonary hemorrhage at presentation.; Pancytopenia symptoms: fatigue, dyspnea, pallor (anemia); easy bruising, petechiae, mucosal bleeding (thrombocytopenia); fever, recurrent infections (neutropenia); Constitutional:…Middle-aged adult with marked leukocytosis (often 100-500K), left-shifted granulocytosis with all stages of myeloid maturation, basophilia, and splenomegaly.; Often asymptomatic — diagnosed on incidental leukocytosis (~40-50% of cases); Fatigue, malaise, weight loss, low-grade fever, night sweats (constitutional symptoms); Early…
Workup / key labs≥20% myeloid blasts in bone marrow or peripheral blood (WHO 5th edition); or any blast percentage with recurrent cytogenetic abnormality t(15;17), t(8;21), inv(16)/t(16;16). APL diagnosed by t(15;17) PML-RARA or PML-RARA fusion.; CBC — anemia, thrombocytopenia; WBC may be high, normal, or low; circulating blasts often visible;…BCR-ABL1 fusion (by cytogenetics t(9;22), FISH, or PCR) in a patient with myeloproliferative features. Phase determined by blast count and clinical criteria.; CBC — marked leukocytosis (often 100-500K), thrombocytosis common, mild anemia variable; eosinophilia and BASOPHILIA characteristic; Peripheral smear — left-shifted…
ImagingCXR if pulmonary symptoms; chest CT for febrile neutropenia evaluation; Echocardiogram before anthracycline therapy; CT or MRI head if neurologic symptomsAbdominal exam / ultrasound to document spleen size; Echocardiogram baseline before nilotinib/ponatinib (cardiovascular risk)
First-line treatmentInduction chemotherapy '7+3': cytarabine (continuous infusion × 7 days) + anthracycline (daunorubicin or idarubicin × 3 days) — standard for fit patients; Addition of midostaurin for FLT3-mutated AML (RATIFY trial); gilteritinib for FLT3-mutated relapsed/refractory; Older or unfit patients: venetoclax (BCL-2 inhibitor) + hypomethylating…Tyrosine kinase inhibitor (TKI) — imatinib, dasatinib, nilotinib, bosutinib, or asciminib (first-line options; asciminib FDA-approved for newly diagnosed chronic phase in 2024); ponatinib for T315I mutation or failure of multiple TKIs; Imatinib (Gleevec) — first-generation, well-tolerated, long-term safety data; standard initial therapy…

Drill Acute Myeloid Leukemia vs Chronic Myeloid Leukemia questions on FirstPassPA

Turn this comparison into retention. 7,200+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Answer the 2 free questions above → Get today's free question →

Full outlines

Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) All 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.